加纳和肯尼亚5岁以下儿童疟疾、脑膜炎和死亡发病率:RTS,S/AS01E疟疾疫苗推广前的前瞻性队列研究(2016至2022年)
该研究在加纳和肯尼亚三个站点对5岁以下儿童开展疾病监测,包括前瞻性队列事件监测和医院为基础监测,共纳入23427名儿童。在5-17月龄组模拟接种后1年风险期内,脑膜炎和脑型疟疾发病率均为每10万人年28例(95%CI 9-65),全因死亡率为每10万人年643例(95%CI 531-771)。观察到的脑膜炎和脑型疟疾发病率处于既往发表范围内,而儿童死亡率较低。
要点
- 5-17月龄组模拟接种后1年风险期内脑膜炎和脑型疟疾发病率均为每10万人年28例(95%CI 9-65)。
- 5-17月龄组全因死亡率为每10万人年643例(95%CI 531-771)。
- 住院期间发生特殊关注不良事件的儿童有11例(0.1%)。
核心结论
- 观察到的脑膜炎和脑型疟疾发病率处于既往发表范围内,而儿童死亡率较低,提示近期降低5岁以下儿童死亡率的努力已产生效果。
- 本研究数据具有公共卫生用途,并将作为持续评估RTS,S/AS01E获益-风险的基线证据。
研究设计与样本
- 该疾病监测研究结合两种方法:对两个年龄组(6-12周和5-17月龄)入组儿童进行前瞻性队列事件监测,以及针对未入组前瞻性队列儿童开展医院为基础疾病监测。
- 研究在加纳和肯尼亚三个站点开展,最终分析共纳入23427名儿童:6-12周龄组9032名,5-17月龄组9694名,医院为基础疾病监测4701名。
主要发现
- 在5-17月龄组(对应WHO推荐的RTS,S/AS01E接种年龄),模拟接种后1年风险期内脑膜炎和脑型疟疾发病率均为每10万人年28例(95%CI 9-65)。
- 住院期间发生特殊关注不良事件的儿童有11例(0.1%)。
- 5-17月龄组全因死亡率为每10万人年643例(95%CI 531-771)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The RTS,S/AS01E malaria vaccine was introduced in selected communities of Ghana, Kenya, and Malawi in 2019 under a WHO-coordinated pilot programme. The scarcity of background disease incidence rates might hamper the assessment of vaccine safety and effectiveness. We aimed to determine the incidence rates of malaria, meningitis, and death, and health outcomes leading to hospital admission in children younger than 5 years enrolled before RTS,S/AS01E implementation. Interim results from EPI-MAL-002 up to Oct 5, 2018, were reported previously. Here, we report results from the final analysis of the pre-vaccine introduction study. METHODS: This disease surveillance study combined two approaches: (1) prospective cohort event monitoring (home visits scheduled to mimic a future four-dose RTS,S/AS01E vaccination schedule [ie, a simulated vaccination schedule], with additional visits after the simulated schedule and continuous disease monitoring of outpatient visits and hospital admission) in children enrolled in two age groups (6-12 weeks [6-12W] and 5-17 months [5-17M]), and (2) hospital-based disease surveillance for children not enrolled in the prospective cohort, in three sites in Ghana and Kenya. Key outcomes were rates of meningitis, malaria, adverse events of special interest, other adverse events leading to hospital admission, all-cause mortality, and malaria-attributable mortality. FINDINGS: The final analysis included 23 427 children: 9032 in the 6-12W age group, 9694 in the 5-17M age group, and 4701 in hospital-based disease surveillance. In the 5-17M age group (corresponding to the WHO-recommended age for RTS,S/AS01E vaccination), the incidence rates of meningitis and cerebral malaria within an at-risk period of 1 year after the simulated vaccination schedule were both equal to 28 (95% CI 9-65) per 100 000 person-years. There were 11 (0·1%) children with an adverse event of special interest during hospital admission. In the 5-17M age group, the all-cause mortality rate was 643 (95% CI 531-771) per 100 000 person-years. INTERPRETATION: Observed incidence of meningitis and cerebral malaria were in the previously published range, whereas childhood mortality was lower, suggesting that the recent efforts to reduce mortality in children younger than 5 years have been impactful. Data from this study have public health use and will form the baseline evidence for ongoing evaluation of the benefit-risk of RTS,S/AS01E. FUNDING: GSK and PATH.
引用
- Asante KP, Bozonnat MC, Savic M, et al. Incidence rates of malaria, meningitis, and mortality in children younger than 5 years: a prospective cohort study in Ghana and Kenya before the roll-out of the RTS,S/AS01E malaria vaccine from 2016 to 2022. Lancet Glob Health. 2025. PMID: 40288396. doi:10.1016/S2214-109X(25)00022-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。